Clade Therapeutics
Clade Therapeutics is a biopharmaceutical company established in 2020 and based in Cambridge, Massachusetts. The company specializes in the discovery and development of scalable, off-the-shelf stem cell-based medicines aimed at treating a variety of diseases, including cancer and autoimmune disorders. Clade Therapeutics integrates advancements in stem cell biology, immunology, regenerative medicine, and gene editing to create next-generation cell therapies. Its initial focus centers on developing therapies utilizing T cells and other immune cells, thereby enhancing the accessibility and effectiveness of stem cell-derived treatments for patients.
Gadeta
Acquisition in 2023
Gadeta is a research and development company focused on creating immunotherapies for cancer treatment. The company has developed a technology platform utilizing combinatorial T cell receptor exchange (CTE) to optimize gamma delta (γδ) T-cell receptors (TCRs), which exhibit enhanced anti-cancer activity. Gadeta's primary product, T Cells Engineered To Express A Defined Gamma Delta TCR (TEGs), demonstrates significant therapeutic potential against both hematological and solid tumors. By employing high-affinity γδ TCRs on αβ T cells, Gadeta's approach aims to improve the proliferation capacity of these T cells, thereby providing healthcare institutions and cancer patients with innovative solutions to combat advanced malignancies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.